AR061567A1 - PURE COMPOUNDS ENANTIOMERICALLY FOR THE TREATMENT OF PROLIFERATIVE DISORDERS - Google Patents
PURE COMPOUNDS ENANTIOMERICALLY FOR THE TREATMENT OF PROLIFERATIVE DISORDERSInfo
- Publication number
- AR061567A1 AR061567A1 ARP070102738A ARP070102738A AR061567A1 AR 061567 A1 AR061567 A1 AR 061567A1 AR P070102738 A ARP070102738 A AR P070102738A AR P070102738 A ARP070102738 A AR P070102738A AR 061567 A1 AR061567 A1 AR 061567A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituted
- unsubstituted
- alkylenehydroxy
- alkoxycarbonyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 230000002062 proliferating effect Effects 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 239000000543 intermediate Substances 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 abstract 1
- -1 C1-4 alkylenehydroxy Chemical group 0.000 abstract 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 abstract 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003435 aroyl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 125000006413 ring segment Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se refiere además a intermediarios puros enantioméricamente de la misma, para procesos para la preparacion del compuesto puro enantioméricamente y sus intermediarios, y para una composicion farmacéutica que comprende el compuesto puro enantioméricamente. El compuesto de la formula (1) es util para el tratamiento de enfermedades o desordenes transmitidos por la inhibicion de la ciclina dependiente de la quinasa, como ser el cáncer. Reivindicacion 1: Compuesto puro enantioméricamente representado por la siguiente formula (1) o un metabolito, prodroga, sal farmacéuticamente aceptable, solvato farmacéuticamente aceptable o polimorfo de los mismos; en donde R1 es fenilo, que se encuentra no sustituido o sustituido por 1, 2, o 3 sustituyentes idénticos o diferentes seleccionados de: halogeno, nitro, ciano, alquilo C1-4, fluorometilo, difluorometilo, trifluorometilo, alcoxi C1-4, hidroxilo, carboxi, alcoxicarbonilo C1-4, alquilenohidroxilo C1-4, CONH2, CONR5R6, SO2NR5R6, cicloalquilo, NR5R6 y SR7; o es un heterociclo, que es un anillo saturado, parcialmente no saturado o aromático que contiene cinco o seis átomos en el anillo de los cuales 1, 2 o 3 son heteroátomos idénticos o diferentes seleccionados de: nitrogeno, oxígeno y azufre, y donde el heterociclo se encuentra no sustituido o sustituido por 1, 2, o 3 sustituyentes idénticos o diferentes seleccionados de: halogeno, nitro, ciano, alquilo C1-4, fluorometilo, difluorometilo, trifluorometilo, alcoxi C1-4, hidroxilo, carboxi, alcoxicarbonilo C1-4, alquilenohidroxilo C1-4, CONH2, CONR5R6, SO2NR5R6, cicloalquilo, NR5R6 y SR7; en donde R5 y R6 se seleccionan independientemente de: hidrogeno, alquilo C1-4, alcoxicarbonilo C1- 4, alquilcarbonilo C1-4, arilo; o R5 y R6 juntos con el átomo de nitrogeno al cual están unidos podrán formar un anillo de cinco o seis miembros que podrá contener opcionalmente un heteroátomo adicional; y R7 podrá seleccionarse de hidrogeno, alquilo C1-4, arilo, SR10 en donde R10 podrá seleccionarse de alquilo C1-4, alquilo o arilo; R2 y R3 se seleccionan independientemente de: halogeno, hidroxilo y OR8; en donde R8 se encuentra sustituido o no sustituido por alquilo C1-10, alcanoil C1- 4, aroil sustituido o no sustituido; R4 es alquilenohidroxilo C1-4; y R9 es hidrogeno o alquilo C1-4.It also refers to enantiomerically pure intermediates thereof, for processes for the preparation of the enantiomerically pure compound and its intermediates, and for a pharmaceutical composition comprising the enantiomerically pure compound. The compound of the formula (1) is useful for the treatment of diseases or disorders transmitted by the inhibition of cyclin dependent kinase, such as cancer. Claim 1: Pure compound enantiomerically represented by the following formula (1) or a metabolite, prodrug, pharmaceutically acceptable salt, pharmaceutically acceptable solvate or polymorph thereof; wherein R1 is phenyl, which is unsubstituted or substituted by 1, 2, or 3 identical or different substituents selected from: halogen, nitro, cyano, C1-4 alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, C1-4 alkoxy, hydroxyl , carboxy, C1-4 alkoxycarbonyl, C1-4 alkylenehydroxy, CONH2, CONR5R6, SO2NR5R6, cycloalkyl, NR5R6 and SR7; or is a heterocycle, which is a saturated, partially unsaturated or aromatic ring containing five or six ring atoms of which 1, 2 or 3 are identical or different heteroatoms selected from: nitrogen, oxygen and sulfur, and where the heterocycle is unsubstituted or substituted by 1, 2, or 3 identical or different substituents selected from: halogen, nitro, cyano, C1-4 alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, C1-4 alkoxy, hydroxyl, carboxy, C1- alkoxycarbonyl 4, C1-4 alkylenehydroxy, CONH2, CONR5R6, SO2NR5R6, cycloalkyl, NR5R6 and SR7; wherein R5 and R6 are independently selected from: hydrogen, C1-4 alkyl, C1-4 alkoxycarbonyl, C1-4 alkylcarbonyl, aryl; or R5 and R6 together with the nitrogen atom to which they are attached may form a five or six membered ring that may optionally contain an additional heteroatom; and R7 may be selected from hydrogen, C1-4 alkyl, aryl, SR10 wherein R10 may be selected from C1-4 alkyl, alkyl or aryl; R2 and R3 are independently selected from: halogen, hydroxyl and OR8; wherein R8 is substituted or unsubstituted by C1-10 alkyl, C1-4 alkanoyl, substituted or unsubstituted aroyl; R4 is C1-4 alkylenehydroxy; and R9 is hydrogen or C1-4 alkyl.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2006/052002 WO2007148158A1 (en) | 2006-06-21 | 2006-06-21 | Enantiomerically pure flavone derivatives for the treatment of poliferative disorders and processes for their preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR061567A1 true AR061567A1 (en) | 2008-09-03 |
Family
ID=37744533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070102738A AR061567A1 (en) | 2006-06-21 | 2007-06-21 | PURE COMPOUNDS ENANTIOMERICALLY FOR THE TREATMENT OF PROLIFERATIVE DISORDERS |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8563596B2 (en) |
| EP (1) | EP2046738B1 (en) |
| JP (1) | JP5498782B2 (en) |
| KR (1) | KR101209397B1 (en) |
| CN (1) | CN101472888B (en) |
| AR (1) | AR061567A1 (en) |
| AU (1) | AU2006344987B8 (en) |
| BR (1) | BRPI0621777A2 (en) |
| CA (1) | CA2655789C (en) |
| DK (1) | DK2046738T3 (en) |
| ES (1) | ES2491140T3 (en) |
| IL (1) | IL195850A0 (en) |
| MX (1) | MX2008016398A (en) |
| NZ (1) | NZ574266A (en) |
| PT (1) | PT2046738E (en) |
| TW (1) | TWI461420B (en) |
| WO (1) | WO2007148158A1 (en) |
| ZA (1) | ZA200810756B (en) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7915301B2 (en) | 2002-07-08 | 2011-03-29 | Piramal Life Science Limited | Inhibitors of cyclin dependent kinases and their use |
| US7884127B2 (en) | 2002-07-08 | 2011-02-08 | Pirimal Life Sciences Ltd. | Inhibitors of cyclin dependent kinases and their use |
| AU2006346193C1 (en) | 2006-07-07 | 2014-02-20 | Piramal Enterprises Limited | An enantioselective synthesis of pyrrolidine-substituted flavones |
| TWI461194B (en) * | 2009-05-05 | 2014-11-21 | Piramal Entpr Ltd | Pyrrolidine Substituted Flavones as Radio Sensitizers |
| WO2011097522A2 (en) | 2010-02-05 | 2011-08-11 | Whitehead Institute For Biomedical Research | Combination methods for treatment of disease |
| KR20130027476A (en) | 2010-02-26 | 2013-03-15 | 피라말 엔터프라이지즈 리미티드 | Pyrrolidine substituted flavones for the treatment of inflammatory disorders |
| CA2794676A1 (en) | 2010-03-29 | 2011-10-06 | Piramal Enterprises Limited | Cytokine inhibitors |
| WO2012069972A1 (en) | 2010-11-19 | 2012-05-31 | Piramal Life Sciences Limited | A pharmaceutical combination for the treatment of breast cancer |
| TW201242597A (en) | 2011-03-14 | 2012-11-01 | Piramal Life Sciences Ltd | A synergistic pharmaceutical combination for the treatment of pancreatic cancer |
| UY34013A (en) * | 2011-04-13 | 2012-11-30 | Astrazeneca Ab | ? CHROMENONE COMPOUNDS WITH ANTI-TUMORAL ACTIVITY ?. |
| TW201300105A (en) * | 2011-05-31 | 2013-01-01 | Piramal Life Sciences Ltd | A synergistic pharmaceutical combination for the treatment of squamous cell carcinoma of head and neck |
| US20140142159A1 (en) | 2011-06-24 | 2014-05-22 | Piramal Enterprises Limited | Compounds for the treatment of cancers associated with human papillomavirus |
| US20140348950A1 (en) | 2012-01-13 | 2014-11-27 | Piramal Enterprises Limited | Pyrrolidine- substituted flavone derivatives for prevention or treatment of oral mucositis |
| WO2014018741A1 (en) | 2012-07-27 | 2014-01-30 | Emory University | Heterocyclic flavone derivatives, compositions, and methods related thereto |
| KR101389407B1 (en) * | 2012-08-27 | 2014-05-27 | 한림대학교 산학협력단 | Implant for spine fixation |
| WO2014049515A1 (en) * | 2012-09-25 | 2014-04-03 | Piramal Enterprises Limited | Pyrrolidine substituted flavones for treatment of renal cystic diseases |
| EP3369730B1 (en) | 2012-11-05 | 2020-08-05 | Emory University | 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto |
| US20140199728A1 (en) | 2013-01-14 | 2014-07-17 | Amgen Inc. | Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture |
| WO2014128524A1 (en) * | 2013-02-19 | 2014-08-28 | Piramal Enterprises Limited | An improved process for preparation of an intermediate of the pyrrolidine substituted flavones |
| WO2014128523A1 (en) * | 2013-02-19 | 2014-08-28 | Piramal Enterprises Limited | A process for preparation of an intermediate of the pyrrolidine substituted flavones |
| WO2014140695A1 (en) * | 2013-03-15 | 2014-09-18 | Piramal Enterprises Limited | Solid oral formulation of a pyrrolidine substituted flavone compound |
| CN117731786A (en) | 2013-07-12 | 2024-03-22 | 皮拉马尔企业有限公司 | Pharmaceutical combination for the treatment of melanoma |
| DK3148532T3 (en) | 2014-05-28 | 2021-04-26 | Piramal Entpr Ltd | Pharmaceutical Combination Comprising a CDK Inhibitor and a Thioredoxin Reductase Inhibitor for the Treatment of Cancer |
| NZ757763A (en) | 2016-03-28 | 2025-07-25 | Presage Biosciences Inc | Pharmaceutical combinations for the treatment of cancer |
| HUE066348T2 (en) | 2018-08-07 | 2024-07-28 | Univ Emory | Heterocyclic flavone derivatives, compositions, and methods related thereto |
| AU2019322858A1 (en) * | 2018-08-14 | 2021-04-01 | Mei Pharma, Inc. | Combination therapy |
| CN113195000A (en) | 2018-12-21 | 2021-07-30 | 第一三共株式会社 | Combination of antibody-drug conjugates and kinase inhibitors |
| CA3136599A1 (en) * | 2019-04-11 | 2020-10-15 | Mei Pharma, Inc. | Voruciclib poly morphs and methods of making and using thereof |
| CN110028475B (en) * | 2019-05-13 | 2022-07-01 | 中国药科大学 | Novel CDK9 inhibitor based on benzopyran structure, its preparation method and application |
| IL302925A (en) * | 2020-11-19 | 2023-07-01 | Mei Pharma Inc | Treatment of KRAS mutant cancers |
| CN114957182B (en) * | 2022-03-30 | 2024-03-15 | 中国药科大学 | USP8 inhibitor containing flavone skeleton structure and application thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN164232B (en) | 1986-04-11 | 1989-02-04 | Hoechst India | |
| JP3451099B2 (en) | 1991-12-06 | 2003-09-29 | 株式会社日立製作所 | External storage subsystem |
| TWI331034B (en) * | 2002-07-08 | 2010-10-01 | Piramal Life Sciences Ltd | Inhibitors of cyclin-dependent kinases and their use |
| US7271193B2 (en) * | 2002-07-08 | 2007-09-18 | Nicholas Piramal India, Ltd. | Inhibitors of cyclin-dependent kinases and their use |
| US8017651B2 (en) | 2002-11-22 | 2011-09-13 | Bionexus, Ltd. | Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia |
-
2006
- 2006-06-21 PT PT67658039T patent/PT2046738E/en unknown
- 2006-06-21 US US12/305,815 patent/US8563596B2/en active Active
- 2006-06-21 JP JP2009515971A patent/JP5498782B2/en active Active
- 2006-06-21 MX MX2008016398A patent/MX2008016398A/en not_active Application Discontinuation
- 2006-06-21 KR KR1020097001021A patent/KR101209397B1/en not_active Expired - Fee Related
- 2006-06-21 NZ NZ574266A patent/NZ574266A/en unknown
- 2006-06-21 EP EP06765803.9A patent/EP2046738B1/en active Active
- 2006-06-21 WO PCT/IB2006/052002 patent/WO2007148158A1/en not_active Ceased
- 2006-06-21 BR BRPI0621777-0A patent/BRPI0621777A2/en not_active IP Right Cessation
- 2006-06-21 AU AU2006344987A patent/AU2006344987B8/en active Active
- 2006-06-21 CA CA2655789A patent/CA2655789C/en active Active
- 2006-06-21 DK DK06765803.9T patent/DK2046738T3/en active
- 2006-06-21 ES ES06765803.9T patent/ES2491140T3/en active Active
- 2006-06-21 CN CN200680055077.2A patent/CN101472888B/en active Active
-
2007
- 2007-06-20 TW TW096122190A patent/TWI461420B/en not_active IP Right Cessation
- 2007-06-21 AR ARP070102738A patent/AR061567A1/en unknown
-
2008
- 2008-12-10 IL IL195850A patent/IL195850A0/en active IP Right Grant
- 2008-12-19 ZA ZA2008/10756A patent/ZA200810756B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006344987B8 (en) | 2013-07-11 |
| PT2046738E (en) | 2014-08-29 |
| AU2006344987A2 (en) | 2009-01-29 |
| HK1126761A1 (en) | 2009-09-11 |
| AU2006344987B2 (en) | 2012-11-15 |
| CA2655789A1 (en) | 2007-12-27 |
| NZ574266A (en) | 2011-10-28 |
| TW200813030A (en) | 2008-03-16 |
| CN101472888A (en) | 2009-07-01 |
| MX2008016398A (en) | 2009-01-21 |
| WO2007148158A1 (en) | 2007-12-27 |
| AU2006344987A1 (en) | 2007-12-27 |
| TWI461420B (en) | 2014-11-21 |
| KR20090023705A (en) | 2009-03-05 |
| ZA200810756B (en) | 2013-05-29 |
| EP2046738A1 (en) | 2009-04-15 |
| CA2655789C (en) | 2014-04-01 |
| KR101209397B1 (en) | 2012-12-06 |
| ES2491140T3 (en) | 2014-09-05 |
| JP5498782B2 (en) | 2014-05-21 |
| US20100179210A1 (en) | 2010-07-15 |
| JP2009541294A (en) | 2009-11-26 |
| CN101472888B (en) | 2014-02-26 |
| BRPI0621777A2 (en) | 2013-03-12 |
| IL195850A0 (en) | 2009-09-01 |
| EP2046738B1 (en) | 2014-06-11 |
| DK2046738T3 (en) | 2014-08-04 |
| US8563596B2 (en) | 2013-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR061567A1 (en) | PURE COMPOUNDS ENANTIOMERICALLY FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | |
| ES2509820T3 (en) | Indazole derivatives as kinase inhibitors for cancer treatment | |
| MX2021009763A (en) | 3-(1-OXO-5-(PIPERIDIN-4-IL)ISOINDOLIN-2-IL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF. | |
| CY1121699T1 (en) | TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS | |
| SA522433155B1 (en) | Trisubstituted ring compounds | |
| EA201070864A1 (en) | NEW HETEROCYCLIC COMPOUNDS | |
| AR118805A2 (en) | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES | |
| EP4295852A3 (en) | Piperidine derivatives as inhibitors of cyclin dependent kinase 7 (cdk7) | |
| AR070531A1 (en) | PIM KINASE INHIBITORS AND METHODS FOR USE | |
| AR054560A1 (en) | SPIROPIPERIDINE AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| AR068115A1 (en) | DERIVED FROM PIRAZOLCARBOXILICO ACID PRODUCTION METHOD OF THE SAME AND FUNGICIDE | |
| AR062111A1 (en) | DERIVATIVES OF BETA-D-GLUCOPIRANOSIL INDOL, METHOD OF PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES AS ANTI-DIABETIC AGENTS. | |
| MX2020008570A (en) | Arginase inhibitors and methods of use thereof. | |
| AR048362A1 (en) | TETRAHYDRONAFTIRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION OF THE SAME | |
| PE20060937A1 (en) | SULFONYLBENZIMIDAZOLE DERIVATIVES AS CANNABINOID RECEPTOR 2 (CB2) AGONISTS | |
| PE20200445A1 (en) | MAGL PYRAZOLIC INHIBITORS | |
| AR069607A1 (en) | INHIBITORS OF THE ESTEAROIL-COA DESATURASA | |
| PH12012500867A1 (en) | Ethynyl derivatives | |
| CU20210023A7 (en) | PYRIDINYL 1,2-OXABOROLAN-2-OL PHOSPHODIESTERASE 4 SUBSTITUTE PHENYL INHIBITORS | |
| PE20161369A1 (en) | DIHYDROPYRIDINONE MONOACILGLYCEROL INHIBITORS 2 (MGAT2) SUBSTITUTE WITH TETRAZOLONE | |
| AR073331A1 (en) | DERIVATIVES OF QUINOLEIN, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND THEIR USE IN THE TREATMENT OF DISEASES MEDIATED BY THE GLYCINE ANTAGONISM B. | |
| CY1116391T1 (en) | ETHINYLIC PRODUCERS AS MGLUR5 POSITIVE ALLOY REGULATORS | |
| AR056103A1 (en) | COMPOUNDS OF (PIRAN-PIPERIDINIL) BENZIMIDAZOL, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, PREPARATION PROCESS AND USES IN THE TREATMENT OF AFFECTIONS MEDIATED BY AGONISTS OF MUSCARINIC RECEIVER M1 | |
| NZ767900A (en) | Pyrazo-tetrahydroisoquinoline derivatives as dopamine d1 receptor positive modulators | |
| AR097721A1 (en) | ETHYLENE DERIVATIVES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |